Toth Financial Advisory’s Rigel Pharmaceuticals RIGL Stock Holding History

Toth Financial Advisory’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-35	Closed	-$1.37K	–	1083
2026 Q2	$1.37K	Buy	+35	New	+$1.08K	﹤0.01%	794

Other funds holding RIGL

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Burney Company Reston, Virginia $3.66B AUM 27.59% 1-Year Est. Return

Venture Visionary Partners Sylvania, Ohio $3.82B AUM 21.33% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

GWM

GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

TCM

Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return

Toth Financial Advisory's RIGL Position: Q3 2026 in Review

Toth Financial Advisory sold out of Rigel Pharmaceuticals (RIGL) in Q3 2026, closing a stake of 35 shares — an estimated $1.37K sold.

Toth Financial Advisory first reported a position in RIGL in Q2 2026 and held it in 1 quarter. The position peaked at $1.37K in Q2 2026. 12 funds tracked by Wall St. Rank hold RIGL as of Q3 2026.

Toth Financial Advisory reported no remaining Rigel Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Toth Financial Advisory sold 35 Rigel Pharmaceuticals shares in Q3 2026, an estimated $1.37K.
Toth Financial Advisory first reported a position in Rigel Pharmaceuticals in Q2 2026 and held it in 1 quarter.
Toth Financial Advisory's Rigel Pharmaceuticals position peaked at $1.37K in Q2 2026.
12 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2026.

Based on Toth Financial Advisory's 13F filing for Q3 2026, filed 8 Oct 2026.